CD19-BAFF CAR-T
/ Shanghai Yake Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 14, 2024
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Zhejiang University | Not yet recruiting ➔ Recruiting
CAR T-Cell Therapy • Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
April 09, 2024
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=45 | Recruiting | Sponsor: Zhejiang University | Not yet recruiting ➔ Recruiting
CAR T-Cell Therapy • Enrollment open • Immunology
April 04, 2024
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Zhejiang University
New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
February 28, 2024
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=45 | Not yet recruiting | Sponsor: Zhejiang University
New P1 trial • Immunology
1 to 4
Of
4
Go to page
1